Proceedings · Session S-764 · filed October 10, 2026

Technology Transfer & IPSession paper

Stephenson Harwood publishes UK safe harbour primer for life sciences

Stephenson Harwood's Life Sciences A-to-Z series adds an entry on the UK's new Technology Transfer Block Exemption, framing the safe harbour for IP licensing teams and R&D managers.

By Sophie Lindqvist3 min read634 words

Summary

  • Stephenson Harwood published a new entry in its Life Sciences A to Z practitioner series
  • The entry is titled 'S is for Safe Harbour: What you need to know about the UK's new Technology Transfer Block Exemption'
  • Stephenson Harwood assigned the TTBE the letter 'S' in its glossary rather than 'T'
  • The firm frames the piece as a practitioner primer for life sciences counsel and R&D managers
  • The entry sits inside a glossary format that maps regulatory and commercial concepts to letters of the alphabet

Stephenson Harwood has added an entry on the United Kingdom's new Technology Transfer Block Exemption (TTBE) to its "Life Sciences A to Z" practitioner series, the law firm confirmed through the publication.

The entry, titled "S is for Safe Harbour: What you need to know about the UK's new Technology Transfer Block Exemption," sits inside a glossary format that maps regulatory and commercial concepts to letters of the alphabet. Stephenson Harwood assigned the TTBE the letter "S" rather than "T," a framing that prioritises practitioner shorthand over the regulation's formal name.

Why is the firm flagging this now?

UK competition authorities replaced the inherited EU technology transfer block exemption with a domestic regime after the Brexit transition. Stephenson Harwood's decision to publish an "S is for Safe Harbour" entry signals that the firm considers the TTBE a routine checkpoint for life sciences counsel handling licensing and IP-transfer matters.

What does the TTBE entry tell R&D managers?

The title — "What you need to know" — frames the piece as a practitioner primer rather than an academic review. Readers working in pharma, biotech, medtech, or university technology transfer offices will use the entry to brief themselves on which technology transfer arrangements fall within the safe harbour, which sit outside it, and what conditions attach to exempt agreements.

The piece lands in a working context where R&D managers negotiate patent licences, know-how transfers, and collaborative research contracts that allocate IP between parties. The TTBE shapes whether those agreements receive automatic exemption from competition law scrutiny or instead require individual assessment.

Where does the TTBE touch R&D workflows?

For research-based organisations, the safe harbour governs three recurring deal types. University spin-out licences that transfer patented inventions from a research institution to a newly formed company; cross-licences between competitors developing overlapping therapeutics; and joint venture agreements where parties pool patents to share development risk. Each transaction requires counsel to check whether the deal's structure meets the TTBE's conditions, including market-share thresholds and the licensing categories covered.

The presence of a domestic TTBE also reshapes how UK-based R&D teams structure deals with European counterparts. Cross-border licences between a UK licensor and an EU licensee now sit under separate safe harbours, requiring separate assessments rather than a single EU-wide review. Stephenson Harwood's guidance will speak directly to that bifurcation.

How should teams treat law firm commentary?

Treat the entry as one input among several. Stephenson Harwood is a UK law firm with a commercial interest in life sciences clients retaining the firm for technology transfer work, and its framing of the safe harbour will reflect that lens. R&D managers should read the entry alongside the Competition and Markets Authority's published TTBE text and any accompanying guidance, pressure-testing practitioner interpretation against regulator language.

What questions should R&D teams raise?

The TTBE raises a recurring set of questions for licensing teams. Does the deal fall inside the safe harbour at signing, and will it remain inside on each renewal date as product pipelines evolve? Are the contracting parties competitors within the regulation's definition, a classification that can shift as portfolios change? Does the licence cover only exempt IP categories, or does it include ancillary restrictions that fall outside the block exemption?

Forward look

The first wave of UK technology transfer agreements drafted against the domestic TTBE will define the body of practice that follows. As those agreements reach renewal cycles and as disputes surface, the Competition and Markets Authority's published interpretations will harden. Stephenson Harwood's A-to-Z entry now joins the working library that counsel and technology transfer offices consult when structuring such deals, and updates to that library will track the regulator's evolving position.

via Google News: Technology transfer (Source)

Filed under

  • technology-transfer
  • ttbe
  • life-sciences
  • uk-regulation
  • patent-licensing
Share this article:

More from Sophie Lindqvist

Sophie Lindqvist

Show full bio

Correspondent covering business strategy at Hypothesis Wire.

149 articles

References

  1. EU Rolls Out Revised Technology Transfer Block Exemption Regulation
  2. EU Adopts Revised Technology Licensing Rules, Skadden Confirms
  3. Revised EU TTBER Reshapes Antitrust Safe Harbor for R&D Licensing
  4. EU technology transfer regime: licensing rules face rewrite
  5. WTO Members Plot Next Steps on Technology Transfer After MC14

« Previous articleNext article »